GeoVax Labs, Inc. (Atlanta, GA) will launch its Phase 2a human vaccine trials in 12 sites across North and South America.
GeoVax Labs, Inc. (Atlanta, GA) will launch its Phase 2a human vaccine trials in 12 sites across North and South America. These trials will be conducted in collaboration with the National Institutes of Health (NIH) and the HIV Vaccine Trials Network (HVTN).
Trial site arrangements and other details of the study were confirmed in a recent meeting held in Seattle, WA, between the HVTN and GeoVax’s scientific personnel. The Phase 2a clinical trial will involve 150 vaccinees and 75 placebo participants. The vaccine regimen employs a two-component “prime–boost strategy.” Trial participants will first be administered a GeoVax HIV-1 DNA vaccine which “primes” the immune system, followed by the second vaccine, GeoVax’s HIV-1 MVA (modified Vaccinia virus) boost. Both vaccines express the three major proteins of the AIDS virus. These proteins mimic more than 50% of the components of the AIDS virus (HIV-1) but cannot cause AIDS. GeoVax AIDS vaccines are designed to prevent the HIV-1 virus infection that causes acquired immunodeficiency disease (AIDS).
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.